Introduction
Presently for all clinicians & surgeons, one of the greatest concern and anxiety is the emergence of drug resistance to the pathogenic organisms. Since last 80 years of antimicrobial use-from the sulphonamides of the 1930s to the present carbapenems-resistance always emerges, even when it is least expected. Most of the important bacterial pathogens have developed resistance to the major antibacterial options and it is now a global healthcare threat. Clinical and economic impact of this is devastating, especially in developing countries like ours. Recent estimates in the European Union for the costs of selected multidrug resistant bacteria are 25,000 deaths per year and 1.5 million EUR 1 . In the USA $ 20-30,000 per patient excess hospital costs, excess social cost of 10-18 million and double the morbidity (attributable mortality 6.5%) 2 . In a recent survey of European Intensive Care Unit physicians, 82% considered multidrug resistance to be the major problem 3 . In developing countries including Bangladesh 70% of hospital acquired neon. Unit infections cannot be treated with WHO recommended drugs 4 .
According to Dr. David Livermore of Healthcare Protection Agency, UK-an expert in this field,'Bacterial resistance will continue to become more complex. Thirty years ago, 11 different plasmid-mediated ß-lactamases were known and from a single isoelectric focusing one could identify the enzyme present in any isolate with >90% certainty. It was rare then for an isolate to have more than one acquired ß-lactamase. Nowadays, over 250 acquired ß-lactamases are known and it is commonplace for an isolate to have multiple enzymes or confusingly, multiple variants of the same enzyme.'
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Pneumococcal resistance
Streptococcus pneumoniae remains one of the major pathogens in children and adults worldwide. Over the past 3 decades, antimicrobial resistance among Streptococcus pneumoniae, the most common cause of community-acquired pneumonia (CAP), has escalated dramatically. Currently 15 to 30% of S. pneumoniae worldwide are multidrug-resistant (MDR) (i.e., resistant to 3 classes of antibiotics). Globally, it is estimated that, it is responsible for more than 5,000,000 pneumonia and approximately 100,000 meningitis cases, the whole being associated with 10,000,000 bacteremia cases every year.
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Nosocomial MRSA
Methicillin resistant S. aureus (MRSA) isolates were once confined largely to hospitals, other health care environments, and patients frequenting these facilities. Community-associated MRSA strains have rapidly disseminated among the general population in many countries and affect patients with and without exposure to the health care environment. Several studies have demonstrated increased mortality, length of hospitalization and hospital costs from infections due to MRSA.
7
Gram negative infections
Unlike the West, where Gram positive infections are the problem, the Indian subcontinent is plagued by resistance in the Gram negative organisms. Drug resistant tuberculosis and malaria also add to our woes. Gram negative organisms account for most of nosocomial infections. E. coli, Klebsiella, Pseudomonas and Acinetobacter are the main culprits. Carbapenem and Ciprofloxacin resistance is 30% to 50%. In general Fluoroquinolone resistance in Gram negative bacteremia is upwards of 70%. 8 Salmonella is the third most common cause of bacteremia after E. coli and Klebsiella, contributing to over a quarter of cases. Among many factors that can affect the emergence and spread of antimicrobial resistance, antimicrobial abuse or misuse is the most important and a basic driving force to induce the resistance. Antibiotics are the most common drugs to be used inappropriately and unreasonably as in the clinical practice, abuse or misuse of antibiotics may not result in immediate harm or problems to the patients.
Current status of antimicrobial uses in Asia
In Turkey, 28% of the subjects were storing antibiotics at home. 19.1% of the subjects were taking antibiotics by themselves without any professional recommendations for sore throat, fever or cough. 10 In Japan, 60% of the patients who have visited clinics or hospitals were given antibiotics for non-bacterial URI. Third-generation cephalosporins were the most commonly prescribed drug class (46%) followed by macrolides (27%) and quinolones (16%).
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In China, recent data showed that 77.8% of inpatients were given antibiotics among which 55 % were prescribed two or more kinds of antibiotics. In 58% of cases, antibiotics were given therapeutically, but only 39 out of 1,025 cases were investigated microbiologically. 12 In Korea, 54.7% of the physicians prescribed antibiotics for acute bronchitis, which was presumed viral infection. 13 In Hong Kong, several surveys showed that antibiotics are being prescribed for ca. 60-80% of cold and flu outpatient visits. In Indonesia, 84% of inpatients in two teaching hospitals received antibiotics. Therapeutic uses accounted for 53%, prophylactic uses in 15 % and unclear indication in 32% of cases. Overall, only 21% of antibiotics uses were evaluated appropriate. 14 In India, according to a recent survey, overall antibiotic prescription rate was 81.8% in primary and secondary healthcare facilities. It was significantly higher in rural hospitals than in urban hospitals. The most common antibiotics used were penicillin, sulphonamides, and fluoroquinolones. 15 In Bangladesh the picture is similar to India and majority of the pharmacists/drug-sellers advice and sell antibiotics without prescription.
Novel testing methods for determining antimicrobial resistance include real-time PCR, mass spectroscopy and next generation sequencing which are costly and not easily available in our developing countries.
How to tackle
To effectively tackle the major resistance problems legislative measures are required.
The interventions should target
Regulation in the use of Antibiotics Increasing awareness about Resistance Standardizing effective surveillance Strengthening Infection Control to ensure effective isolation, hand hygiene compliance, environmental disinfection and antimicrobial stewardship.
Comprehensive strategies should be implemented to control and prevent the emergence and the spread of antimicrobial resistance. The most important strategy is to promote the appropriate use of antimicrobial agents in the clinical practice.
A national strategy should be a multi-faceted approach and include strengthening antibiotic resistance surveillance, developing and implementing antibiotic guidelines for practitioners, conducting antibiotic utilization studies, improving access to and upgrading the quality of microbiological diagnostic facilities, increasing public awareness of antibiotic resistance and controlling and regulating the use of antibiotics for both medicinal and non- 
